

**Glaxo Laboratories Limited**  
(Registered number: 00239893)

**Directors' report and financial statements**  
**for the year ended 31 December 2017**

**Registered office address:**  
980 Great West Road  
Brentford  
Middlesex  
TW8 9GS  
England



**Glaxo Laboratories Limited**  
**(Registered number: 00239893)**

**Directors' report and financial statements**  
**for the year ended 31 December 2017**

<b>Contents</b>	<b>Pages</b>
Directors' report	1-2
Balance sheet	3
Notes to the financial statements	4-5

**Glaxo Laboratories Limited**  
**(Registered number: 00239893)**

**Directors' report for the year ended 31 December 2017**

The Directors present their report on Glaxo Laboratories Limited (the 'Company') and the financial statements for the year ended 31 December 2017.

**Principal activities, review of business and future developments**

The Company, a member of the Glaxosmithkline Group (the 'Group'), did not trade during the year. Therefore, the Company is considered dormant as defined in section 1169 of the Companies Act 2006 throughout the year. There was no transfer to or from reserves for the year. The Directors are of the opinion that the Company will remain dormant for the foreseeable future.

**Directors and their interests**

The Directors of the Company who were in office during the year and up to the date of signing the financial statements were as follows:

O Dubianskij (appointed on 31 January 2017)  
A Burns  
Glaxo Group Limited  
Edinburgh Pharmaceutical Industries Limited

No Director had, during the year or at the end of the year, any material interest in any contract of significance to the Company's business with the exception of the Corporate Directors, where such an interest may arise in the ordinary course of business. A corporate director is a legal person (legal entity of the Group), as opposed to a natural person (an individual) director.

**Directors' indemnity**

Each of the Directors benefits from a third party indemnity given by the Company. This indemnity is in respect of liabilities incurred by the Director in the execution and discharge of their duties. The indemnity remained applicable throughout the financial year and up to the date of signing.

**Statement of Directors' responsibilities**

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 101 "Reduced Disclosure Framework", and applicable law). Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

**Glaxo Laboratories Limited**  
**(Registered number: 00239893)**

**Directors' report for the year ended 31 December 2017**

**Statement of Directors' responsibilities (continued)**


The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. The Directors are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**Audit and small company exemption**

The Company, having not traded during the year, satisfied the conditions for exemption from audit as specified in section 480 of the Companies Act 2006 for the year ended 31 December 2017.

This report has been prepared taking advantage of the small companies exemption in accordance with section 415A of the Companies Act 2006.

On behalf of the Board

A handwritten signature in black ink, appearing to read 'AGB' or similar, with a horizontal line underneath.

A Burns  
Director

16 APRIL 2018

**Glaxo Laboratories Limited**  
(Registered number: 00239893)

**Balance sheet**  
**as at 31 December 2017**

	Note	2017 £	2016 £
<b>Current assets</b>			
Trade and other receivables	3	66,555	66,555
<b>Net current assets</b>		<b>66,555</b>	<b>66,555</b>
<b>Net assets</b>		<b>66,555</b>	<b>66,555</b>
<b>Equity</b>			
Share capital	4	39,000	39,000
Retained earnings		27,555	27,555
<b>Shareholder's equity</b>		<b>66,555</b>	<b>66,555</b>

During the financial year and preceding financial year, the Company undertook no accounting transactions. Consequently, the Company made neither a profit, a loss nor any other recognised gains or losses during the year and therefore has not prepared an income statement or separate statement of other comprehensive income.

For the year ending 31 December 2017, the Company was entitled to an exemption for audit under section 480 of the Companies Act 2006 relating to dormant companies.

The members have not required the Company to obtain an audit of its accounts for the year in question in accordance with section 476; and

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The financial statements on pages 3 to 5 were approved by the Board of Directors on *16 APRIL 2018* and signed on its behalf by:



A Burns  
Director

*16 APRIL 2018*

**Glaxo Laboratories Limited**  
**(Registered number: 00239893)**

**Notes to the financial statements for the year ended 31 December 2017**

**1 Presentation of the financial statements**

**General information**

Glaxo Laboratories Limited is a dormant company. The Company is a private company, limited by shares, and is incorporated and domiciled in the UK (England). The address of the registered office is 980 Great West Road Brentford Middlesex TW8 9GS.

**2 Summary of significant accounting policies**

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied, unless otherwise stated.

**(a) Basis of preparation**

The financial statements have been prepared in accordance with Financial Reporting Standard 100 Application of Financial Reporting Requirements ("FRS 100") and Financial Reporting Standard 101 Reduced Disclosure Framework ("FRS 101").

These financial statements have been prepared on the going concern basis under the historical cost convention, and in accordance with the Companies Act 2006.

***Disclosure exemptions adopted***

In preparing these financial statements the Company has taken advantage of all disclosure exemptions conferred by FRS 101. Therefore these financial statements do not include:

- The following paragraphs of IAS 1, 'Presentation of financial statements':
  - 10(d), (statement of cash flows),
  - 16 (statement of compliance with all IFRS),
  - 38A (requirements for minimum of two primary statements, including cash flow statements),
  - 38B-D (additional comparative information),
  - 40A-D (requirements for a third balance sheet),
  - 111 (cash flow statement information), and
  - 134 - 136 (capital management disclosures).
- IAS 7, 'Statement of cash flows'
- Paragraph 30 and 31 of IAS 8 'Accounting policies, changes in accounting estimates and errors' (requirement for the disclosure of information when an entity has not applied a new IFRS that has been issued but is not yet effective);
- Paragraph 17 of IAS 24, 'Related party disclosures' (key management compensation);
- The requirements in IAS 24, 'Related party disclosures' to disclose related party transactions entered into between two or more wholly owned members of a group.

The financial statements of GlaxoSmithKline plc can be obtained as described in note 2(b).

The preparation of financial statements in conformity with FRS 101 requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company's accounting policies. As the Company is dormant, the Directors confirm that no significant accounting judgements or critical estimates apply to the Company.

**Glaxo Laboratories Limited**  
**(Registered number: 00239893)**

**Notes to the financial statements for the year ended 31 December 2017**

**(b) Ultimate and immediate parent undertaking**

The Company is a wholly owned subsidiary of the ultimate parent company. GlaxoSmithKline plc, a company incorporated in England and Wales, is the Company's ultimate parent undertaking and controlling party. The largest and smallest group of undertakings for which group financial statements are prepared and which include the results of the Company are the consolidated financial statements of GlaxoSmithKline plc. Copies of the consolidated financial statements can be obtained from the Company Secretary, GlaxoSmithKline plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS. The immediate parent undertaking is Glaxo Wellcome UK Limited. These financial statements are separate financial statements.

**(c) Trade and other receivables**

Trade and other receivables are carried at original invoice amount less any provisions for doubtful debts. Provisions are made where there is evidence of a risk of non-payment, taking into account ageing, previous experience and general economic conditions. When a trade or other receivable is determined to be uncollectable it is written off, firstly against any provisions available and then to the income statement.

Subsequent recoveries of amounts previously provided for are credited to the income statement. Long-term receivables are discounted where the effect is material.

**3 Trade and other receivables**

	2017 £	2016 £
Amounts owed by Group undertakings	66,555	66,555

The amounts owed by group undertakings are unsecured, interest free and are repayable on demand.

**4 Share capital**

	2017 Number of shares	2016 Number of shares	2017 £	2016 £
<b>Issued and fully paid</b>				
Ordinary Shares of 100p each (2016: 100p each)	39,000	39,000	39,000	39,000
	39,000	39,000	39,000	39,000

**5 Employees**

The Company has no employees (2016: nil).

**6 Directors' remuneration**

During the year the Directors of the Company, with the exception of the Corporate Directors, were remunerated as executives of the Group and received no remuneration in respect of their services to the Company (2016: £nil). Corporate Directors received no remuneration during the year, either as executives of the Group or in respect of their service to the Company (2016: £nil).